USA – ArrePath, a Princeton, NJ-based anti-infective drug discovery company addressing the global health challenge of drug resistant infections, raised $20m in seed financing.
The Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures co-led the financing, which also included Viva BioInnovator, Arimed Capital, PTX Capital, and Nor’easter Ventures. The company intends to use the funds to advance its proprietary, machine learning (ML)-based platform for the discovery of new classes of anti-infectives to overcome antimicrobial resistance (AMR). ArrePath also announced that Dr. Lloyd Payne has been named President and CEO. Dr. Payne, who serves on the Novo REPAIR Impact Fund Scientific Selection Board and the AMR Action Fund Scientific Advisory Board, brings more than 25 years of scientific and business leadership in the discovery and development of anti-infectives. Prior to joining ArrePath, Dr. Payne served at Evotec, as Executive Vice President, Head of Anti-infectives, where he led the company’s anti-infective discovery and translational microbiology businesses. Previously, he founded Euprotec, a life sciences company focused on anti-infective drug discovery and development and served as its CEO until its acquisition by Evotec.ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections. The company’s approach leverages a novel technology platform to enable the discovery and development of new and differentiated antibiotics by decoding the complex behavior of bacteria when exposed to new chemical entities (known as ‘bacterial autopsies’), leading to the efficient elucidation of biological mechanisms of action. Utilizing proprietary machine learning and imaging technologies, the platform has the ability to identify, optimize, and rapidly develop new classes of anti-infectives with differentiated mechanisms of action compared to those exhibited by existing drugs.04/03/2022
